摘要
慢性阻塞性肺疾病(COPD)是一种以气流受限和呼吸困难为特征的肺部疾病;2型糖尿病(T2DM)是一种以血糖代谢异常为特征的疾病。COPD与T2DM之间存在一定联系,也常构成慢性共病,给患者造成巨大的风险。二甲双胍是目前用于T2DM的一线降糖药物,可通过改善胰岛素拮抗降低糖尿病患者血糖。近年来,随着研究的不断深入,二甲双胍针对COPD表现出抗炎、抗氧化应激、抗感染等作用,对COPD及伴有T2DM并发症的COPD患者具有潜在的临床效益,有望成为新的T2DM合并COPD慢性共病的治疗途径。该文对二甲双胍治疗T2DM合并COPD相关研究进行综述,以期为COPD合并T2DM的治疗提供参考。
Chronic obstructive pulmonary disease(COPD)is a lung disease characterized by airflow limitation and dyspnea,and type 2 diabetes mellitus(T2DM)is characterized by abnormal blood glucose metabolism.COPD and T2DM are closely interconnected and often constitute chronic comorbidities,posing huge patient risks.Metformin is currently the first-line hypoglycemic drug for T2DM,which can reduce blood glucose in diabetic patients by improving insulin antagonism.In recent years,with the continuous deepening of research,metformin has shown anti-inflammatory,anti-oxidative stress,anti-infection,and other effects on COPD,and it has potential clinical benefits in COPD patients and COPD patients with T2DM comorbidities.It is expected to become a new treatment approach for chronic comorbidity of T2DM combined with COPD.This article reviewed the related studies of metformin in treating COPD combined with T2DM,hoping to provide a research reference for the treatment of COPD combined with T2DM.
作者
朱宝强
陶雪
刘雨蒙
龙恩武
叶云
ZHU Baoqiang;TAO Xue;LIU Yumeng;LONG Enwu;YE Yun(School of Pharmacy,Southwest Medical University,Luzhou 646000,China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Chengdu 610072,China;Department of Pharmacy,Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)
出处
《医药导报》
CAS
北大核心
2023年第11期1711-1717,共7页
Herald of Medicine
基金
四川省科技计划项目(2021YFS0197)
四川省人民医院临床研究及转化基金(2017LY16)。
关键词
二甲双胍
慢性阻塞性肺疾病
糖尿病
2型
Metformin
Chronic obstructive pulmonary disease
Diabetes mellitus,type 2
